Resistance to immune checkpoint inhibitors and the tumor microenvironment

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, particularly for skin cancer.
• However, primary and acquired resistance limit their effectiveness in many patients.
• Addressing ICI resistance is a critical unmet need in clinical oncology.

Purpose of the Study:

• To review and categorize the mechanisms underlying resistance to immune checkpoint inhibitors (ICIs).
• To focus on resistance mechanisms related to T-cell activation processes within the tumor microenvironment (TME).
• To provide a framework for developing novel strategies to overcome ICI resistance.

Main Methods:

• Literature review and synthesis of existing research on ICI resistance.
• Classification of resistance mechanisms based on T-cell activation pathways.
• Focus on three key areas: antigen recognition, T-cell migration/infiltration, and effector functions.

Main Results:

• ICI resistance is complex and patient-specific, often involving T-cell dysfunction in the TME.
• Mechanisms are categorized into impaired antigen recognition, reduced T-cell infiltration, and compromised T-cell effector functions.
• Understanding these specific T-cell related pathways is crucial for identifying resistance drivers.

Conclusions:

• Resistance to ICIs is frequently linked to disruptions in T-cell activation processes.
• Categorizing resistance into antigen recognition, T-cell migration, and effector functions provides a structured approach.
• Further research into these mechanisms will facilitate the development of more effective cancer immunotherapies.